

EVALUERVE



Global Healthcare Industry

M&A and Capital Market Landscape Q1'24 Review

Contents








Global Healthcare M&A Q1'24: A Healthy Start to the Year!	3
Healthcare Funding: Investors Optimistic as Markets Start to Rebound	4
Healthcare SPACs: Innovative Deal Structures are the Need of the Hour.....	5
ESG in Healthcare M&a: A Crisis-resilient Long-term Value Creation	5
Outlook 2024: Spotlight on Reposition and Transformation	6
Author.....	9
Evalueserve Disclaimer	10

Global Healthcare M&A Q1'24: A Healthy Start to the Year!


The global healthcare market witnessed healthy broad-based deal activity in Q1'24 as dealmakers continued to look and generate value in the current challenging market environment. The COVID-19 knock-on effects, labour force displacement, geopolitical unpredictability and liquidity scarcity that dominated talks previously have stabilized to a certain extent, thereby providing a conducive environment for deal discussions. The ability to identify, negotiate and realize value from increasingly complex partnerships and alternative collaboration models continue to drive deal making and serve as a key competitive advantage.

The sector witnessed numerous 'big ticket' agreements, especially in the pharmaceuticals and biotech sub-sector given their significant war chest, which drove investors' confidence and set the tone for the remainder of the year. However, lack of mega deals resulted in subdued y-o-y figures owing to strong base effect. Nonetheless, dealmakers continued to amend their strategies to bridge the valuation gaps and conducted deeper analyses of the targets, thereby extending duration of negotiations and due diligence.

Key M&A sentiments observed during Q1'24:


-  Lower valuations and heightened boardroom CEO confidence across healthcare subsectors drove deal volume though lack of mega deals muted y-o-y growth (high base effect)
-  Portfolio realignment is happening among the strategics to divest non-core or under-performing assets; the proceeds of which are expected to be used in ramping of R&D, technology, and scale
-  Rapid paradigm shift towards utilizing data and actionable insights to implement person-centric network/product strategies across sub-sectors
-  Uncertain geopolitical environment and higher for longer interest cycle continued to put pressure on justifying synergies and ROIs
-  The increasing demand for GLP-1 medications may lead to more deals in the weight loss industry, as start-ups compete with Big Pharma
-  Sponsors remained cautious and revised their expectations to factor in the changing deal making landscape with lower valuations justifying 'firepower' deployment during the year
-  Traditional initial public offerings made a strong comeback as the primary investor exit method

Global Healthcare Regional M&A YTD 2024 (US\$ bn)



Source: Refinitiv; deals as of April 18, 2024

Global Healthcare M&A Volume Analysis (US\$ bn)




In Q1'24, investors continued to view the healthcare sector in terms of its historical status as a "go-to" market amidst uncertainty and engaged in 'big ticket' deals, highlighting the industry's resilience and attractiveness as strong long-term value generator

Healthcare Funding: Investors Optimistic as Markets Start to Rebound

The Debt Capital Market (DCM) showed pockets of optimism in Q1'24 with issuers largely been able to push out near-term maturities amid tight credit conditions. Majority of the deals were related to refinancing and repricing which were driven by the lack of new supply. Investors also exhibited greater risk tolerance as banks have been more active, resulting in increased M&A financing in the syndicated debt markets and more favorable pricing as the first quarter continued. Aided by strong investor interest and tighter spreads, borrowers refinanced more costly private credit with more affordable widely syndicated loans. Overall, looking ahead we expect refinancing deals to remain under focus in 2024 with anticipation of modest interest rate cuts, likely to give an improved market tone for deals.

The resurgence in Equity Capital Market (ECM) activity after 2 years was driven by the perception of stability in interest rates and inflation, strong base effect (soft y-o-y figures) and better economic growth prospects and listing companies' willingness to accept valuation resets. Majority of the deal activity was restricted to Life Science and Biotech companies. The IPO backlog continues to be robust with companies planning to get themselves listed before changes in the political landscape later in the year (such as the US election). This should ideally drive volume in the coming quarters this year.

Global Healthcare Capital Markets Activity YTD 2024 (US\$ bn)




Source: Refinitiv; deals as of April 18, 2024

Healthcare SPACs: Innovative Deal Structures are the Need of the Hour

We continue to believe that the success or should we say the existence of the SPACS going forward will be heavily dependent upon their ability to adapt to the changing financial legislation and competitive environment. The heightened regulatory scrutiny along with excessive redemptions during de-SPAC, a virtually non-existent PIPE market, overcrowding and "SPAC-off" processes have diminished the traditional appeal to investors. Though funding (SPAC IPOs) had dried up in the last one-year, innovative deal structures and better due diligence have shown some signs of revival of investors' faith and stability. In terms of deal volumes, Q1'24 mirrored pre-pandemic numbers in terms of de-SPACs. However, for the first time in over four years there is scarcity in the SPAC market, which in turn has provided opportunities for established sponsors, as witnessed in MedTech, HealthTech and Biotech sub-sectors during the year. Spotlight has been on overseas targets with sponsor economics being more negotiable aided by the rising number of redemption mitigation mechanisms.

Healthcare SPAC M&As (de-SPACs) Remained 'Normalized' in YTD 2024



Source: Refinitiv; deals as of March 31, 2024

ESG in Healthcare M&A: A Crisis-resilient Long-term Value Creation

In the healthcare industry, an environmental, social, and governance (ESG) framework aims to create sustainable energy and waste management systems, encourage investments in community health, and address unmet medical needs; it also requires leaders to embrace diversity and inclusion as their foremost duties. The COVID-19 pandemic has demonstrated that adhering to ESG factors is key to crisis-resilient long-term value creation. Companies with dynamic business cultures were relatively more resilient during the shutdowns, given their ability to absorb the shock. Globally, investors have started to recognize the potential benefits of announcing an acquisition that is ESG accretive. By directly linking ESG factors to long-term value creation, companies can substantially alleviate investor concerns by de-risking their investments.

The Advent of an 'ESG premium' is Expected to Directly Impact Due Diligence



From a funding standpoint, the cost of capital for companies with better ESG scores is lower than for companies with lesser scores. For example, there is a greater investor demand and better pricing for issuers of many green, social, or sustainable bonds versus traditional (non-ESG) issuances. This trend has also gained prevalence among shareholder activists, who have started to include ESG improvements as an important criterion while targeting companies. Since the start of the COVID-19 pandemic, global issuance of sustainable debt capital across all industries are at an all-time high. As a result, companies are upgrading their disclosures, culture, and practices towards a more ESG-friendly approach.

In the context of M&A, understanding the disparities between buyers and sellers' ESG profiles have become essential for a successful deal. As a result, deal makers continue to place greater emphasis on ESG criteria while screening out assets and determining valuations across geographies and sub-sectors.

Outlook 2024: Spotlight on Repositioning and Transformation

As we look ahead, deal activity is expected to pick up further, especially in the pharma / biotech sub-sectors, given the availability of large dry powder among the major consolidators. Dealmakers, who have been sidelined due to geo-political uncertainty and market volatility, will be eager to structure deals that enable both buyer and seller to transform their business models for the future.

More normalized valuation levels across the healthcare industry, aided by healthy demand from sponsors, the need for replenishing drug pipelines, the buy and build approach of major companies and the revival of the credit market should drive volumes higher in 2024.

In the light of these developments, we foresee the following niche M&A trends to define the overall deal-making for the remainder of 2024:



Geo-political tensions continue to dominate client discussions: An unstable political landscape had disrupted the global supply chains and had 'put the brakes' on the record deal activity that we had witnessed during the pandemic. For deal makers, market timing has become the strongest headwind in the current environment. Dialogues with related parties should carefully weigh-in the challenges of value-creation post-merger.



Estimated dry powder of ~US\$4.0tr among private equity firms: The strong capital position of private equity firms continue to create opportunities for them to assess and capture resilient healthcare assets. Dealmakers have always found a way to navigate uncertainty and make profitable investments even during high market volatility. Contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and MedTech companies look attractive for "go-private" deals given the attractive valuations.



Record levels of deal making firepower is available amongst key pharma consolidators: The top 25 pharma companies is estimated to have ~US\$1.4tr worth of firepower designated for M&A (as per EY report in Jan'24) at the end of 2023. Reduced deal premiums, patent expiry and dearth of innovative in-house pipeline should propel deal activity in 2024.



Innovation continues to be rewarded: We continue to foresee any incremental M&A push to be broad-based across major healthcare sub-sectors, as innovation gets rewarded by investors. These include companies that are/were directly involved in addressing the spread of COVID-19, like those focused on diagnostics and vaccine development, as well as consolidation among medical devices manufacturers, which were severely impacted by restrictions on elective during the start of the pandemic.



Scarcity of attractive assets may serve as a 'deal-breaker': Unprecedented surge in deals in the last few years backed by a 'liquidity flush' had resulted in an overheated market last year. Investment banks might find it tougher to negotiate terms between the parties due to a lack of available white space and valuation gap between buyer and seller especially during high market volatility.



Impact of Inflation Reduction Act (IRA) on pharmaceutical pricing: While it is unclear how the IRA will affect prices in the long run, it is obvious that there will be major effects, possibly for indications and treatments with very large R&D expenditures. As a result, partners are beginning to think about including customized terms in contracts to address the effects on downstream price.



Scrutiny on the rise for Mega M&As: The new merger guidelines that the DOJ and FTC recently finalized will probably result in more stringent regulatory oversight of healthcare transactions. The guidelines, most notably, broaden the range of transactions that FTC will examine for potential anticompetitive effects, meaning that more transactions will be reviewed.



Heightened shareholder activism: Given the market developments, shareholder activism should continue to be focused on M&A, strategic operations and shifts in capital allocation. The activist investors are in a strong position to identify and target companies ripe for activist involvement with focus on extracting value and generating 'alpha' returns.



Key M&A Trends Across Sub-sectors in 2024

Medical Devices

M&As expected to be driven by focus on vertical integration of supply chains, establishing category leadership, and 'buy and build' strategies

Pharma Outsourcing

Consolidation expected among major players, pharma companies and sponsors due to fragmented market, enhanced demand for smarter trial design, biologics, and bioreactor development

Healthcare Technology

M&A hotspot, with rising valuations of healthtech and startups amid the growing importance of contactless healthcare delivery

01

Biopharma

Deployment of record level of dry-powder to replenish drug pipelines and find synergies amid a looming patent cliff and the race to acquire early-stage innovators

02

Healthcare Services

Largely a buyer's market, with capital availability, evolving competitive dynamics, scalability, and commitments to patient-centricity garnering premium valuation

03

04

Diagnostics and Labs

Cash infusions during pandemic expected to be reinvested in core areas or adjacencies in other related businesses

05

06



We continue to view the healthcare industry as a key growth engine for the overall market driven by a paradigm shift in investors' ideology of viewing the sector as more than just a 'defensive' strategy

How Evalueserve Can Help

Evalueserve has extensive experience working with large, mid-market investment, and boutique advisory firms that deal with franchising companies across sectors such as sports, education, home improvement, entertainment, health and wellness, and food and beverages. Our resources are experienced and qualified to support clients with in-depth analysis and detailed presentations. The Evalueserve team works as an extended team for clients and helps them in matters such as identifying and profiling potential targets / buyers with relevant metrics, financial and operational benchmarking, financial modelling and valuation, benchmarking of franchise financials, confidential information memorandums, detailed management presentations, indications of interests, live deal support, and deal marketing.

Read more about our end-to-end deal support at [Corporate Finance Research Consulting | Evalueserve](#).

To know more about our investment banking offerings, visit our webpage: [Investment Banking Advisory - Evalueserve](#).

Author



Arjun Paul

Manager – Corporate and Investment Banking LoB

Arjun.Paul@evalueserve.com

Arjun has 9+ years of experience in working with offshore investment banking teams, with a focus on the healthcare industry.

About EVALUESERVE

Evalueserve is a leading analytics partner to Fortune500 companies. Powered by mind+machine™, Evalueserve combines insights emerging from data and research with the efficiency of digital tools and platforms to design impactful solutions. A global team of 4,000+ experts collaborates with clients across 15+ industries.

Connect with us

Connect with us on 

If you are interested in speaking with Evalueserve about how your organisation can adapt for tomorrow, please contact us at info@evalueserve.com or, for more information, visit www.evalueserve.com.

Evalueserve Disclaimer

The information contained in this report has been obtained from reliable sources. The output is in accordance with the information available on such sources and has been carried out to the best of our knowledge with utmost care and precision. While Evalueserve has no reason to believe that there is any inaccuracy or defect in such information, Evalueserve disclaims all warranties, expressed or implied, including warranties of accuracy, completeness, correctness, adequacy, merchantability and / or fitness of the information.